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ORIGINAL RESEARCH
Catheter Ablation Improves Mortality and 
Other Outcomes in Real- World Patients 
With Atrial Fibrillation
Pil-Sung Yang, MD*; Jung-Hoon Sung, MD, PhD*; Eunsun Jang, MS; Hee Tae Yu, MD, PhD; Tae-Hoon Kim, MD; 
Jae-Sun Uhm, MD, PhD; Jong-Youn Kim, MD, PhD; Hui-Nam Pak, MD, PhD; Moon-Hyoung Lee, MD, PhD;  
Boyoung Joung, MD, PhD
BACKGROUND: It is still controversial whether catheter ablation for atrial fibrillation (AF) improves survival and other outcomes 
in patients with AF. This study evaluated whether ablation reduces death and other events in nationwide real- world Asian 
patients with AF.
METHODS AND RESULTS: From the Korean National Health Insurance Service database, 194 928 adult patients (aged ≥18 years) 
with newly diagnosed AF were treated with ablation or medical therapy (antiarrhythmic or rate control drugs) between January 
1, 2005, and December 1, 2015. Among these patients, this study included 9185 with ablation and 18 770 with medical 
therapy. The time at risk was counted from the first medical therapy, and ablation was analyzed as a time- varying covari-
ate. Inverse probability of treatment weighting was used to correct for differences between the groups. After weighting, the 
2 cohorts had similar background characteristics. During a median (25th, 75th percentiles) follow- up of 43 (19, 81) months, 
ablation of AF was associated with lower incidence and risk of composite outcome, including death, heart failure admission, 
and stroke/systemic embolism (2.5 and 6.4 per 100 person- years, respectively; hazard ratio [HR], 0.47; 95% CI, 0.43–0.52; 
P<0.001), all- cause death (1.0 and 3.6 per 100 person- years; HR, 0.41; 95% CI, 0.36–0.47; P<0.001), heart failure admission 
(0.7 and 1.9 per 100 person- years; HR, 0.43; 95% CI, 0.37–0.50), and ischemic stroke/systemic embolism (1.1 and 2.8 per 100 
person- years; HR, 0.39; 95% CI, 0.34–0.44) than medical therapy.
CONCLUSIONS: Ablation may be associated with lower risk of death, heart failure admission, and ischemic stroke/systemic 
embolism in real- world Asian patients with AF.
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Atrial fibrillation (AF) is the most common sus-tained cardiac arrhythmia in the general pop-ulation.1–4 AF has enormous socioeconomic 
implications because it increases the risk of mortality 
and morbidity resulting from stroke, congestive heart 
failure, dementia, and impaired quality of life.1–3,5,6 
However, it remains uncertain how much this risk can 
be mitigated by restoring sinus rhythm.
Catheter ablation for AF is superior to antiarrhyth-
mic drugs in decreasing AF recurrences, prolonging 
the time in sinus rhythm, and improving the quality 
of life of patients.7–10 However, its effects on other 
clinical outcomes are not well established. Some 
nonrandomized follow- up studies have reported fa-
vorable outcomes, such as the reduction of ischemic 
stroke and death, in ablated patients.11–13 In a trial 
of ablation versus medical therapy in symptomatic 
patients with AF and heart failure, successful ab-
lation may extend survival and reduce heart failure 
admission.14 In contrast, in the recently performed 
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CABANA (Catheter Ablation Versus Antiarrhythmic 
Drug Therapy for Atrial Fibrillation) trial,15 catheter 
ablation for AF did not significantly reduce the pri-
mary composite end point of death, disabling stroke, 
serious bleeding, or cardiac arrest, compared with 
medical therapy in general AF population. However, 
the estimated treatment effect of catheter ablation in 
this study was affected by the lower- than- expected 
event rates and treatment crossovers. In many stud-
ies, catheter ablation for AF consistently improved 
left ventricular ejection fraction and complication 
rates, including heart failure readmissions in heart 
failure patients with AF.14,16–18 Therefore, the effects 
of AF ablation on the long- term incidence of mortality 
and other outcomes remain unknown.
The objective of this study was to compare the inci-
dences of death, heart failure admission, and ischemic 
stroke/systemic embolism (SE) in real- world patients 
with AF. Moreover, we used “falsification analysis” to 
strengthen the results.
METHODS
All data and materials have been made publicly avail-
able at the National Health Insurance Service (NHIS) 
of Korea. The data can be accessed on the National 
Health Insurance Data Sharing Service homepage of 
the NHIS (http://nhiss.nhis.or.kr). Applications to use 
the NHIS data will be reviewed by the inquiry com-
mittee of research support and, once approved, raw 
data will be provided to the authorized researcher 
with a fee at several permitted sites. This study was 
a retrospective cohort analysis using the national 
health claims database (NHIS- 2016- 4- 009) estab-
lished by the NHIS of Korea. The NHIS is the single 
insurer managed by the Korean government. Most 
Korean citizens (97.1%) are mandatory subscribers to 
the NHIS, and the remaining 3% of the population 
are under the Medical Aid program. As the NHIS da-
tabase contains the information of Medical Aid users, 
it is based on the entire Korean population.1–3,6,19,20 
This study was approved by the institutional review 
board of the Yonsei University Health System (4- 
2016- 0179), and the requirement for informed con-
sent was waived.
Study Population
From the Korean NHIS database covering a popula-
tion 51.5 million inhabitants, 834 735 adult patients 
(aged ≥18 years) were newly diagnosed with AF from 
January 1, 2006, to December 31, 2015. Among 
these patients, the study population included those 
who were treated with ablation or medical therapy 
(antiarrhythmic drugs or rate control drugs). AF was 
diagnosed using the International Classification of 
CLINICAL PERSPECTIVE
What Is New?
• In a nationwide real-world study of Korean 
patients with atrial fibrillation, ablation of atrial 
fibrillation was associated with a 53% lower 
risk of the composite outcome, including 
death, heart failure admission, and stroke/
systemic embolism, compared with medical 
therapy.
• This trend was consistently observed in all sub-
groups regardless of sex, age, heart failure, hy-
pertension, stroke, atrial fibrillation recurrence, 
and anticoagulation.
What Are the Clinical Implications?
• This study provides additional evidence of the 
potential role for ablation in real-world Asian pa-
tients with atrial fibrillation.
• The benefit for ablation might be related to the 
lower risk of heart failure and ischemic stroke/
systemic embolism after ablation.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
CABANA  Catheter Ablation 
Versus Antiarrhythmic 
Drug Therapy for Atrial 
Fibrillation
CASTLE AF  Catheter Ablation for 
Atrial Fibrillation With 
Heart Failure
CHA2DS2-VASc score  congestive heart failure, 
hypertension, age ≥75 
[doubled], diabetes 
mellitus, prior stroke or 
transient ischemic at-
tack [doubled], vascular 
disease, age 65 to 74, 
female
HAS-BLED  hypertension, 
>65 years old, stroke 
history, bleeding history 
or predisposition, liable 
international normalized 




NHIS  National Health 
Insurance Service
SE systemic embolism
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Diseases, Tenth Revision (ICD-10), code I48. To en-
sure diagnostic accuracy, AF was defined as present 
only when it was a discharge diagnosis or con-
firmed at least twice in the outpatient department. 
The AF diagnosis has previously been validated in 
the NHIS database with a positive predictive value of 
94.1%.1–3,6,19,20
For both the ablated and the medical therapy pa-
tients, the time at risk was counted from index date 
of the first medical therapy. In patients who under-
went AF ablation without medical therapy, the time 
at risk was counted from the index date of the first 
ablative procedure. Effect of ablation was analyzed 
as a time- varying exposure. The exclusion criteria 
for both groups were valvular AF, arrhythmia surgery 
(maze and similar procedures), implanted cardiac 
electric device, or heart failure admission. Among 
medical therapy patients, patients who had oral an-
ticoagulants <30 days during the same period were 
additionally excluded. After exclusions, 9185 ablated 
and 18 770 medical therapy patients remained for 
the analysis (Figure 1).
Covariates
Information on comorbidity conditions was obtained 
from inpatient and outpatient hospital diagnoses. 
Baseline comorbidities were defined using medical 
claims and prescription medications before the index 
date. The patients were considered to have comorbidi-
ties when the condition was a discharge diagnosis or 
was confirmed at least twice in an outpatient setting, 
similar to previous studies using NHIS data (Table S1).1–
3,6,19,20 Baseline economic status was determined on 
the basis of the relative economic levels, categorized 
into 10 levels according to their health insurance pre-
miums in the index year. Prescription medication use 
was verified by identifying NHIS database claims within 
90 days before the index date.
Clinical Outcome Events and 
Assessments
The primary clinical outcome was a composite end 
point of all- cause death, heart failure, and ischemic 
stroke/SE. The secondary outcomes were each of 
these outcomes considered separately. Patients 
were followed up until the end of the study period 
(December 31, 2016) or death. Data on vital status 
and date of death were confirmed from the National 
Population Registry of the Korea National Statistical 
Office with the use of a unique personal identification 
number, in which central registration of death was 
conducted on the basis of death certificates.1–3,6,19,20 
This approach provides a complete event ascertain-
ment, because the NHIS and National Statistical 
Office are national organizations covering all Korean 
subjects.
Figure 1. Flowchart of the enrollment and analysis of the study population.
AF indicates atrial fibrillation; ICD, implantable cardioverter- defibrillator; and OAC, oral anticoagulant.
J Am Heart Assoc. 2020;0:e015740. DOI: 10.1161/JAHA.119.015740 4
Yang et al AF Ablation and Mortality
Ischemic stroke was defined from any discharge 
diagnoses (ICD-10 codes I63 and I64) with concomi-
tant brain imaging studies. The accuracy of the diag-
nosis of an ischemic stroke in the NHIS claim data was 
previously validated.1–3,6,19,20 The definitions of clinical 
outcomes are presented in Table S1. The same pa-
tient could have >1 study outcome during the study 
duration, but only the first event of each outcome was 
considered in the study.
Statistical Analysis
Baseline characteristics of participants with and 
without incident AF were compared using Student t 
test and Pearson’s χ2 test. Propensity score overlap 
weighting was used to account for the differences 
in baseline characteristics between patients who un-
derwent ablation and those who were treated with 
medical therapy alone. A propensity score, the prob-
ability of undergoing ablation, was estimated using 
logistic regression based on sociodemographics, 
medical history, concurrent medication use, and AF 
duration (variables in Table  1). The overlap weight 
was calculated as 1- propensity score for the ab-
lated patients, and the propensity score for the drug- 
treated patients. This weight is used to calculate the 
average treatment effect for the overlap population. 
The balance between the treatment populations was 
evaluated by standardized differences of all base-
line covariates using a threshold of 0.1 to indicate 
imbalance.
Incidence rates of events were calculated by di-
viding the number of events by person- times at risk, 
with the 95% CIs estimated by exact Poisson distri-
butions. We compared the incidences of death using 
the weighted log- rank test and plotted weighted failure 
curves. Cox proportional hazards regressions were 
used to compare those patients treated with ablation 
and medical therapy. The Fine and Gray method was 
used to consider death as a competing risk when 
assessing nonfatal outcomes (ie, heart failure and 
stroke/SE when considered separately).21 The propor-
tional hazards assumption was tested on the basis of 
Schoenfeld residuals.22
Sensitivity Analyses
First, we performed subgroup analyses for the pri-
mary composite end point and all- cause death strati-
fied by sex, age, heart failure, hypertension, diabetes 
mellitus, stroke/transient ischemic attack, vascular 
disease, CHA2DS2- VASc score (congestive heart fail-
ure, hypertension, age ≥75 years [doubled], diabe-
tes mellitus, prior stroke or transient ischemic attack 
[doubled], vascular disease, aged 65 to 74 years, fe-
male), cardioversion or repeated ablation, and antico-
agulation. Second, 1:1 propensity score matching was 
used instead of propensity score weighting. Third, we 
conducted a stratified analysis based on whether the 
drug- treated patients were treated with antiarrhythmic 
or with rate control drugs only. Fourth, we conducted 
an analysis between ablated patients and subjects 
without history of AF.
We used “falsification analysis” to determine 
whether ablation was associated with lower rates of 
urinary tract infections, varicella zoster, and fall ac-
cidents that should not be lower with ablation and 
would indicate that the population receiving ab-
lation was different in ways that would result in re-
duced mortality or stroke that had nothing to do with 
ablation.23
A 2- sided P<0.05 was considered significant. 
Statistical analyses were conducted using SAS version 
9.3 (SAS Institute, Cary, NC) and R version 3.3.2 (The 
R Foundation; http://www.R-proje ct.org).
RESULTS
Differences Between Ablated and the 
Medical Therapy Patients
Compared with medical therapy patients, ablated 
patients were more often men, were healthy, and had 
an income in the highest quartile (Table 1). Ablated 
patients were on average 10 years younger and had 
less concomitant diseases. After inverse probabil-
ity of treatment weighting, all baseline characteris-
tics were similar between the 2 groups (Table 1). In 
multivariable analysis, the factors independently as-
sociated with the likelihood of undergoing catheter 
ablation were younger age, income in the highest 
quartile, and comorbidities, including heart failure, 
hypertension, and diabetes mellitus (Table S2).
Ablated patients were younger, were healthy, and 
had fewer comorbidities than antiarrhythmic drug- 
treated (Table S3) and rate control patients (Table S4). 
All baseline characteristics were similar between IPT 
weighted 2 groups.
Improved Primary Outcome in Ablated 
Patients
During a median (25th, 75th percentiles) follow- up of 43 
(19, 81) months, 950 and 6818 cases had weighted 
primary outcome in the ablated and medical therapy 
group with weighted annualized rates of 2.5 and 6.4 
per 100 person- years, respectively (P<0.001) (Table 2). 
The cumulative incidence of primary outcome was sig-
nificantly lower in the ablated group compared with the 
medical group (P<0.001; Figure  2A). Compared with 
patients with medical therapy and after full adjustment 
of clinical variables, the risk of primary outcome was 
reduced by 53% in patients with ablations (hazard ratio 
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[HR], 0.47; 95% CI, 0.43–0.52; P<0.001) (Table 2). The 
risk of primary outcome was reduced in the ablated 
group compared with antiarrhythmic drug- treated 
(HR, 0.51; 95% CI, 0.46~0.56; P<0.001) and rate con-
trol groups (HR, 0.43; 95% CI, 0.40~0.48; P<0.001) 
(Table 2). Subgroup analyses showed that the risk of 
















Age, y 57 (50, 65) 67 (59, 74) 83.6 61 (53, 68) 62 (53, 70) 8.0
Men 76.3 66.6 21.4 72.9 71.4 3.4
High- income status 54.9 45.5 19.0 50.7 49.6 2.3
AF duration, mo 24.4 (7.1, 56.7) 16.8 (2.5, 37.6) 25.8 14.8 (4.3, 42.3) 12.8 (1.1, 37.4) 3.5
Risk scores
CHA2DS2- VASc score 2.0 (1.0, 3.0) 4.0 (2.0, 5.0) 76.7 3.0 (1.0, 4.0) 3.0 (1.0, 4.0) 7.6
mHAS- BLED score* 2.0 (2.0, 3.0) 3.0 (2.0, 4.0) 42.0 1.4 (0.9, 2.7) 2.5 (1.5, 3.4) 5.6
Charlson comorbidity index 3.0 (2.0, 5.0) 4.0 (2.0, 6.0) 43.4 3.0 (2.0, 5.0) 3.0 (2.0, 5.0) 4.2
Hospital frailty risk score 1.1 (0.0, 3.4) 1.8 (0.0, 6.3) 57.6 1.3 (0.0, 4.0) 0.8 (0.0, 4.2) 8.6
Comorbidities
Heart failure 32.0 46.8 30.6 34.5 36.4 3.9
Hypertension 77.0 86.8 25.4 77.4 77.4 <0.1
Diabetes mellitus 13.8 26.4 31.8 19.1 19.7 1.6
Dyslipidemia 81.2 77.4 9.5 77.4 75.8 3.9
Ischemic stroke 15.7 34.4 44.3 21.7 24.0 5.5
TIA 7.8 9.6 6.3 8.3 8.2 0.2
Hemorrhagic stroke 1.3 3.1 12.3 1.9 2.1 1.9
Myocardial infarction 10.4 14.5 12.6 11.3 11.7 1.1
Peripheral arterial disease 10.5 15.3 14.2 11.9 12.3 1.1
Chronic kidney disease 4.0 6.8 12.4 5.3 5.2 0.4
End- stage renal disease 0.5 1.2 7.7 0.9 0.9 0.1
Proteinuria 4.9 6.0 4.7 5.3 5.3 0.2
Hyperthyroidism 18.6 14.4 11.1 15.8 15.2 1.6
Hypothyroidism 15.5 12.2 9.4 12.9 12.4 1.5
Malignancy 18.4 21.3 7.3 18.2 18.9 1.7
COPD 19.6 29.2 22.6 22.2 23.5 3.1
Liver disease 43.5 39.5 8.0 40.6 40.0 1.3
Hypertrophic cardiomyopathy 1.9 3.2 8.7 2.6 2.6 0.4
History of bleeding 28.8 30.7 4.2 28.4 28.3 0.2
Osteoporosis 15.5 25.2 24.4 19.1 19.9 2.0
Sleep apnea 2.0 0.7 11.4 1.2 1.0 1.7
Medication (treatment)
OAC 59.1 71.5 26.3 52.8 54.1 2.6
Antiplatelet agents 73.4 64.4 19.6 63.4 62.0 2.8
ACE inhibitor/ARB 47.4 61.0 27.6 50.8 50.9 <0.1
Diuretics 33.3 56.1 47.0 41.3 42.9 3.3
K- sparing diuretics 6.6 16.4 30.9 9.8 10.8 3.5
Statin 38.6 40.2 3.4 37.1 36.2 1.8
Values are presented as median (quartile 1, quartile 3 [25th, 75th percentiles]) or percentage. ACE indicates angiotensin- converting enzyme; AF, atrial 
fibrillation; ARB, angiotensin II receptor blocker; CHA2DS2- VASc, congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, prior stroke 
or transient ischemic attack (doubled), vascular disease, age 65 to 74 years, female; COPD, chronic obstructive pulmonary disease; mHAS- BLED, modified 
HAS BLED (hypertension, >65 years old, stroke history, bleeding history or predisposition, liable international normalized ratio, ethanol or drug abuse, drug 
predisposing to bleeding); OAC, oral anticoagulant; SMD, standardized mean difference; and TIA, transient ischemic attack.
*mHAS- BLED=hypertension, 1 point; >65 years old, 1 point; stroke history, 1 point; bleeding history or predisposition, 1 point; liable international normalized 
ratio, not assessed; ethanol or drug abuse, 1 point; drug predisposing to bleeding, 1 point.
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primary outcome was reduced in most subgroups 
(Figure 3).
Reduced Mortality in Ablated Patients
The cumulative incidence of all- cause death was sig-
nificantly lower in the ablated group compared with 
the medical group (P<0.001; Figure 2B). Ablation was 
related with lower incidence and 59% lower risk of all- 
cause death (1.0 and 3.6 per 100 person- years; HR, 
0.41; 95% CI, 0.36~0.47; P<0.001) compared with the 
medical therapy. Subgroup analyses showed that the 
risk of all- cause death was reduced in most subgroups 
(Figure 4). The risk of all- cause death was reduced in 
the ablated group compared with antiarrhythmic drug- 
treated (HR, 0.49; 95% CI, 0.42~0.56) and rate control 
groups (HR, 0.40; 95% CI, 0.35~0.46) (Table 2).
Other factors associated with the increased risk of 
all- cause death included end- stage renal disease (HR, 
2.94; 95% CI, 2.24–3.87; P<0.001), older age (per 10-
year increase: HR, 1.89; 95% CI, 1.78–2.01; P<0.001), 
hypertrophic cardiomyopathy (HR, 1.34; 95% CI, 1.14–
1.58; P<0.001), men (HR, 1.30; 95% CI, 1.10–1.53; 
P<0.001), higher CHA2DS2- VASc score (HR, 1.18; 95% 
CI, 1.10–1.25; P<0.001), higher Hospital Frailty Risk 
scores (per 1 increase: HR, 1.05; 95% CI, 1.05–1.06; 
P<0.001), and higher Charlson comorbidity indexes 
(per 1 increase: HR, 1.04; 95% CI, 1.02–1.06; P<0.001).
Heart Failure Admission and Stroke/SE
Ablation was related with lower incidence and risk of 
heart failure admission (0.7 and 1.9 per 100 person- 
years; HR, 0.43; 95% CI, 0.37–0.50; P<0.001) and 
stroke/SE (1.1 and 2.8 per 100 person- years; HR, 0.39; 
95% CI, 0.34–0.44; P<0.001) compared with the medi-
cal therapy (Table 2). The cumulative incidence of heart 
failure admission (P<0.001; Figure 5A) and stroke/SE 
(P<0.001; Figure 5B) was significantly lower in the ab-
lated group compared with the medical therapy group.
The risk of heart failure admission was reduced 
in the ablated group compared with antiarrhythmic 
drug- treated (HR, 0.47; 95% CI, 0.39~0.56; P<0.001) 
and rate control groups (HR, 0.43; 95% CI, 0.37~0.51; 
P<0.001). Ablation was also related with lower risks of 
ischemic stroke/SE in the ablated group compared 


























Medical Therapy (N=18 770) Ablation (N=9185)
Ablation vs medical therapy
Composite† 6818 107 277 6.4 950 38 009 2.5 3.9 (3.6–4.1) 0.47 (0.43–0.52) <0.001
All- cause death 4357 122 235 3.6 420 40 636 1.0 1.2 (1.0–1.4) 0.41 (0.36–0.47) <0.001
Heart failure 2134 115 032 1.9 265 39 238 0.7 1.2 (1.0–1.3) 0.43 (0.37–0.50) <0.001
Stroke/SE 3163 111 494 2.8 420 38 925 1.1 1.8 (1.6–1.9) 0.39 (0.34–0.44) <0.001
Antiarrhythmic drug (N=13 117) Ablation (N=9422)
Ablation vs antiarrhythmic drug
Composite† 4344 81 266 5.3 937 39 507 2.4 3.0 (2.7–3.2) 0.51 (0.46–0.56) <0.001
All- cause death 2413 90 544 2.7 412 42 119 1.0 1.7 (1.5–1.9) 0.49 (0.42–0.56) <0.001
Heart failure 1346 86 196 1.6 258 40 747 0.6 0.9 (0.8–1.1) 0.47 (0.39–0.56) <0.001
Stroke/SE 2100 83 797 2.5 418 40 393 1.0 1.5 (1.3–1.6) 0.42 (0.38–0.48) <0.001
Rate control only (N=7368) Ablation (N=9422)
Ablation vs rate control only
Composite† 3511 54 295 6.5 923 40 039 2.3 4.2 (3.9–4.4) 0.43 (0.40–0.48) <0.001
All- cause death 2223 61 974 3.6 407 42 644 1.0 2.7 (2.4–2.8) 0.40 (0.35–0.46) <0.001
Heart failure 1073 58 495 1.8 251 41 299 0.6 1.2 (1.1–1.4) 0.43 (0.37–0.51) <0.001
Stroke/SE 1710 56 268 3.0 417 40 897 1.0 2.0 (1.8–2.2) 0.34 (0.30–0.39) <0.001
SE indicates systemic embolism.
*Adjusted for age, sex, income, atrial fibrillation duration, CHA2DS2- VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes 
mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65 to 74 years, female), modified HAS- BLED (hypertension, >65 years old, 
stroke history, bleeding history or predisposition, liable international normalized ratio, ethanol or drug abuse, drug predisposing to bleeding) score, hospital 
frailty risk score, Charlson comorbidity index, hypertension, diabetes mellitus, ischemic stroke/transient ischemic attack, myocardial infarction, peripheral 
arterial disease, hypertrophic cardiomyopathy, chronic kidney disease, end- stage renal disease, liver disease, malignancy, hyperthyroidism, hypothyroidism, 
venous thromboembolism, chronic obstructive pulmonary disease, intracranial bleeding, cardioversion, history of bleeding, baseline use of warfarin, non–
vitamin K antagonist oral anticoagulant, aspirin, clopidogrel, β blocker, angiotensin- converting enzyme inhibitor/angiotensin II receptor blocker, dihydropyridine/
nondihydropyridine calcium channel blocker, class Ic and III antiarrhythmic drug, statin, diuretics, digoxin, and oral anticoagulant coverage rate of time at risk.
†The primary clinical outcome was a composite end point of all- cause death, heart failure, and ischemic stroke/SE.
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with antiarrhythmic drug- treated (HR, 0.42; 95% CI, 
0.38–0.48; P<0.001) and rate control groups (HR, 
0.34; 95% CI, 0.30–0.39; P<0.001) (Table 2).
Sensitivity Analyses
The results using 1:1 propensity score matching (instead 
of overlap weights) were similar to the primary results. 
For the primary outcome, the HR was 0.48 (95% CI, 
0.44–0.53; P<0.001) for ablation versus medical therapy, 
0.52 (95% CI, 0.48–0.58; P<0.001) for ablation versus 
antiarrhythmic drug treated, and 0.43 (95% CI, 0.39–
0.48; P<0.001) for ablation versus rate control. Ablation 
was also related with lower risk of all- cause death, heart 
failure, and stroke/SE in 1:1 propensity score matched 
ablated group than medical therapy, antiarrhythmic 
drug- treated, and rate control groups (Table S5).
The comparison between AF ablation and a con-
temporary group of matched patients with no history 
of AF is presented in Table S6. Compared with IPT 
weighted patients without history of AF, the risks of 
primary outcome, all- cause death, heart failure, and 
stroke/SE were not significantly increased in ablated 
patients with AF (Table S6).
There were no significant relationships between 
ablation and any of the falsification end points, except 
varicella zoster virus infection, which had higher risk in 
ablated than rate control groups (Table S7).
DISCUSSION
The main finding of this study was that the risk of pri-
mary outcome was 53% lower in IPT weighted ablated 
patients than in medical therapy patients during a fol-
low- up. Second, patients who underwent AF ablation 
had lower risks of all- cause death, heart failure, and 
ischemic stroke/SE than the medical therapy popula-
tion. This finding suggests that the ablation is associ-
ated with the reduction of mortality in real- world Asian 
AF population, and this effect might be related with the 
reduction of heart failure and ischemic stroke/SE.
Reduction of Mortality and Heart Failure 
Admission by Ablation
In the intention- to- treat analysis of a recent randomized 
controlled trial (CABANA trial), catheter ablation did not 
significantly decrease the primary composite end point 
of death, disabling stroke, serious bleeding, or cardiac 
arrest compared with drug therapy. However, in the 
treatment- received analyses, the HR for catheter abla-
tion versus drug therapy with respect to the primary 
end point and all- cause mortality was 0.67 (95% CI, 
0.50–0.89; P=0.006) and 0.60 (95% CI, 0.42–0.86; 
P=0.005), respectively.15 In the current study, the bet-
ter outcome of the ablation group relative to the non-
ablation group was similar to the improved outcome 
of the “as- treated” ablation group compared with the 
drug therapy group in the CABANA trial. The apparent 
mortality benefit from AF ablation has been observed 
by other real- world studies, with a 54% to 61% reduc-
tion in mortality.12,13,24
In this study, catheter ablation was associated 
with a lower risk of heart failure admission. In many 
studies, including a randomized controlled study, 
catheter ablation for AF consistently improved left 
ventricular ejection fraction and complication rates, 
including heart failure readmissions in heart failure 
patients.14,16–18 The recent CASTLE AF (Catheter 
Ablation for Atrial Fibrillation With Heart Failure) study 
Figure 2. Weighted cumulative incidence curves of primary composite endpoint (A) and all- cause death (B) for ablated and 
medical therapy patients.
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showed that ablation improves outcome in patients 
with AF and heart failure.14
Other Outcomes
The risk of stroke was lower in ablated patients than 
in nonablated patients. Although the preventive effect 
of ablation against stroke in real- world patients has 
been reported,11–13 it was not observed in the CABANA 
trial.15 The loss of benefit of ablation in randomized 
controlled trials might be explained by the fact that 
the included populations are highly selected and do 
not represent typical real- world patients with AF. Trial 
participants tend to have better adherence to medical 
therapies (eg, oral anticoagulants) than patients in rou-
tine practice, and event rates are often lower in trials 
than in real- world practice. Therefore, it may be more 
difficult to detect further risk reduction from ablation 
on top of that from optimal medical therapy within a 
trial, compared with an observational study in which 
guideline- directed medical therapy is underused.
This study showed a strong association between 
ablation and survival. The cause of death was car-
diovascular in patients with AF.25 Theoretically, a re-
duction of cardiovascular mortality could be related 
to fewer strokes and cardiovascular events, as well 
as to reduced worsening of congestive heart failure 
associated with AF.26
Study Limitations
The present study has several limitations. First, studies 
using administrative databases might be susceptible to 
errors arising from coding inaccuracies. To minimize this 
problem, we applied the definition that has been previ-
ously validated in previous studies using the Korean 
Figure 3. Subgroup analyses of the risk of primary composite outcome.
CHA2DS2- VASc indicates congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, prior stroke or transient 
ischemic attack (doubled), vascular disease, age 65 to 74 years, female; HR, hazard ratio; OAC, oral anticoagulant; PYR, person- year; 
and TIA, transient ischemic attack.
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NHIS sample cohort.1–3,6,19,20 Second, causal relation-
ships cannot be established by a retrospective registry 
study like ours, and only associations can be reported. 
Although inverse probability of treatment weighting and 
strict inclusion criteria for control group were used to 
match 2 groups, unknown confounding cannot be neu-
tralized. Third, the information on type of AF and whether 
patients maintained stable sinus rhythm after ablation is 
insufficient. Finally, to indirectly evaluate the relationship 
between rhythm status on primary composite outcome 
or mortality, we added subgroup analysis according to 
“cardioversion or repeated ablation.” However, the exact 
relationships between rhythm status on primary out-
come or mortality were not evaluated.
Figure 4. Subgroup analyses of the risk of death from any cause.
CHA2DS2- VASc indicates congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, 
prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74 years, female; HR, hazard 
ratio; OAC, oral anticoagulant; PYR, person- year; and TIA, transient ischemic attack.
Figure 5. Weighted cumulative incidence curves of heart failure (A) and ischemic 
stroke/systemic embolism (SE) (B) for ablated and medical therapy patients.
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CONCLUSIONS
Ablation may be associated with lower incidences and 
risk of all- cause death in real- world Asian patients with 
AF. This effect might be related with lower risk of heart 
failure and ischemic stroke/SE after ablation.
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Table S1. Definitions and ICD-10 codes used for defining the comorbidities and clinical outcomes. 
 Definitions ICD-10 codes or conditions 
Comorbidities   
Atrial fibrillation Defined from diagnosis* ICD-10: I48 
Heart failure Defined from diagnosis* ICD-10: I11.0, I50, I97.1 
Hypertension Defined from diagnosis* 
ICD-10: I10, I11, I12, I13, I15 and antihypertensive 
medication 
Diabetes mellitus Defined from diagnosis* plus treatment 
ICD-10: E10, E11, E12, E13, E14 
Treatment: all kinds of oral antidiabetics and insulin. 
Dyslipidemia Defined from diagnosis* ICD-10: E78 
Ischemic stroke Defined from diagnosis* ICD-10: I63, I64 
Transient ischemic attack Defined from diagnosis* ICD-10: G45 
Hemorrhagic stroke Defined from diagnosis* ICD-10: I60, I61, I62 
Myocardial infarction Defined from diagnosis* ICD-10: I21, I22, I25.2 
Peripheral arterial disease Defined from diagnosis* ICD-10: I70.0, I70.1, I70.2, I70.8, I70.9 
Chronic kidney disease 
 
Defined from eGFR or diagnosis* 
(if laboratory value was not available, 
diagnosis code was used) 
eGFR <60mL/min per 1.73 m2  
ICD-10: N18, N19 
End-stage renal disease 
Defined from national registry for severe 
illness. 
Patients with end-stage renal disease undergoing 
chronic dialysis or received a kidney transplant. 
Hypertrophic cardiomyopathy 
Defined from at least one records of either 
inpatient or outpatient diagnoses 
ICD-10: I42.1, I42.2 
Sleep apnea Defined from diagnosis* ICD-10: G47.3 
Proteinuria 
Defined from laboratory data (if 
laboratory value was not available, 
diagnosis code was used) 
Urine dipstick proteinuria 1+ or higher (ICD-10: N06, 
N391, N392, R80) 
Osteoporosis Defined from diagnosis* ICD-10: M80, M81, M82 (except M82.0) 
Hyperthyroidism Defined from diagnosis* ICD-10: E05 
Hypothyroidism Defined from diagnosis* ICD-10: E03 
Chronic Liver disease 
Defined from diagnosis of chronic liver 
disease, cirrhosis, and hepatitis 
ICD-10: B18, K70, K71, K72, K73, K74, K76.1 
Chronic obstructive pulmonary 
disease 
Defined from diagnosis* plus treatment 
ICD-10: J42, J43(except J43.0), J44 
Treatment: SABA, SAMA, LABA, LAMA, ICS, 
ICS+LABA, or methylxanthine (>1 months). 
Malignancy 
Defined from diagnoses of cancer (non-
benign) 
ICD-10: C00-C97 
Clinical outcomes   
Ischemic stroke 
Defined from any discharge diagnoses with 
concomitant imaging studies 
ICD-10: I63, I64 
Systemic embolism 
Defined from admission diagnosis or 
related death 
ICD-10: I74, N280 (including renal infarction) 
Heart failure admission 
Defined from admission diagnosis 
(including only main and first sub-
diagnosis) 
ICD-10: I11.0, I50, I97.1 
*To ensure accuracy, comorbidities were established based on one inpatient or two outpatient records of ICD-10 codes in the database. 
eGFR, estimated glomerular filtration rate; ICD-10, International Classification of Diseases-10th Revision. 
 
  
Table S2. Preprocedural factors associated with a likelihood of undergoing catheter ablation. 
 Multivariable adjustment 
 OR (95% CI) p-value 
Demographics   
Age (per 10-year increase) 0.68 (0.65-0.70)  <0.001 
Male 0.78 (0.69-0.88)  <0.001 
High economic status 1.50 (1.41-1.61)  <0.001 
AF duration (per 1-year increase) 1.34 (1.32-1.36)  <0.001 
Risk score (per 1 increase)   
CHA2DS2-VASc score 0.46 (0.42-0.51)  <0.001 
mHAS-BLED score* 0.91 (0.86-0.97)  0.005 
Hospital Frailty Risk Score 1.03 (1.02-1.04)  <0.001 
Comorbidities   
  Heart failure 2.19 (1.94-2.48)  <0.001 
Hypertension 2.04 (1.82-2.29)  <0.001 
Diabetes 1.59 (1.39-1.81)  <0.001 
Ischemic stroke/TIA 7.35 (5.83-9.26)  <0.001 
Myocardial infarction 1.32 (1.16-1.50)  <0.001 
Peripheral arterial disease 2.06 (1.81-2.35)  <0.001 
History of bleeding                     0.80 (0.69-0.91)  0.001 
Hyperthyroidism 1.21 (1.12-1.31)  <0.001 
Hypothyroidism 1.35 (1.23-1.49)  <0.001 
Venous thromboembolism 1.31 (1.13-1.51)  <0.001 
Hemorrhagic stroke 0.72 (0.54-0.96)  0.024 
COPD 0.91 (0.81-1.02)  0.094 
Liver disease 1.46 (1.33-1.60)  <0.001 
*Modified (m) HASBLED = hypertension, 1 point; >65 years old, 1 point; stroke history, 1 point; bleeding history or predisposition, 1 point; 
liable international normalised ratio, not assessed; ethanol or drug abuse, 1 point; drug predisposing to bleeding, 1 point. 
AF, atrial fibrillation; COPD, Chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; TIA, transient ischemic attack. 
 














Demographic       
Age, years  57 (50, 65) 66 (58, 73) 76.2% 60 (52, 68)   61 (52, 69)    2.7% 
Male 76.3% 67.8% 18.8% 73.3% 72.8% 1.3% 
High income status 54.9% 46.1% 17.8% 51.3% 50.5% 1.6% 
AF duration, months 24.4 (7.1, 56.7) 15.5 (2.6, 37.7) 26.4% 14.4 (4.2, 41.5)   11.4 (0.9, 37.5)     3.1% 
Risk scores       
CHA2DS2-VASc score 2.0 (1.0, 3.0) 3.0 (2.0, 5.0) 68.4% 2.0 (1.0, 4.0)     2.0 (1.0, 4.0)       1.7% 
mHAS-BLED score* 2.0 (2.0, 3.0) 3.0 (2.0, 4.0) 36.6% 1.6 (1.0, 2.7)  2.3 (1.1, 3.3)   5.5% 
Charlson comorbidity index  3.0 (2.0, 5.0) 4.0 (2.0, 6.0) 38.5% 3.0 (2.0, 5.0)     3.0 (2.0, 5.0)       0.6% 
Hospital frailty risk score  1.1 (0.0, 3.4) 1.5 (0.0, 5.6) 52.3% 1.2 (0.0, 3.8)    0.7 (0.0, 3.6)       3.0% 
Comorbidities       
Heart failure 32.0% 44.9% 26.7% 33.4% 33.7% 0.8% 
Hypertension 77.0% 85.7% 22.4% 76.3% 75.4% 2.1% 
Diabetes 13.8% 24.9% 28.5% 18.0% 18.0% 0.2% 
Dyslipidemia 81.2% 78.6% 6.5% 77.4% 76.0% 3.2% 
Ischemic stroke 15.7% 32.5% 39.9% 20.5% 21.3% 2.2% 
TIA 7.8% 9.5% 5.8% 8.1% 7.9% 0.7% 
Hemorrhagic stroke 1.3% 2.7% 10.1% 1.7% 1.8% 0.4% 
Myocardial infarction 10.4% 13.6% 9.8% 10.9% 10.8% 0.2% 
Peripheral arterial disease 10.5% 14.3% 11.6% 11.4% 11.4% 0.2% 
Chronic kidney disease 4.0% 6.3% 10.4% 5.0% 4.7% 1.3% 
End stage renal disease 0.5% 1.1% 6.5% 0.8% 0.8% 0.8% 
Proteinuria 4.9% 6.0% 4.6% 5.3% 5.2% 0.4% 
Hyperthyroidism 18.6% 15.0% 9.4% 16.0% 15.7% 1.1% 
Hypothyroidism 15.5% 12.4% 9.0% 13.0% 12.5% 1.3% 
Malignancy 18.4% 20.9% 6.4% 17.9% 18.3% 1.0% 
COPD 19.6% 28.1% 20.1% 21.6% 22.1% 1.0% 
Liver disease 43.5% 39.8% 7.4% 40.8% 40.2% 1.1% 
Hypertrophic cardiomyopathy 1.9% 3.3% 9.4% 2.6% 2.5% 0.4% 
History of bleeding                     28.8% 30.2% 3.1% 28.1% 27.7% 0.8% 
Osteoporosis 15.5% 24.5% 22.8% 18.7% 18.7% 0.1% 
Sleep apnea 2.0% 0.8% 9.9% 0.3% 1.3% 1.2% 
Medication (Treatment)       
OAC 59.1% 70.4% 23.8% 50.4% 50.5% 0.3% 
Antiplatelet agents 73.4% 63.5% 21.5% 63.0% 61.3% 3.5% 
ACE-inhibitor/ARB                     47.4% 59.6% 24.7% 49.4% 48.5% 1.8% 
Diuretics 33.3% 54.1% 42.8% 39.7% 39.8% 0.1% 
K sparing diuretics 6.6% 15.2% 27.8% 9.1% 9.4% 0.9% 
Statin 38.6% 41.2% 5.3% 36.9% 36.0% 1.9% 
Values are presented as median (Q1, Q3, quartiles [25th and 75th percentiles]) or %. *Modified HAS-BLED=hypertension, 1 point: >65 years 
old, 1 point: stroke history, 1 point: bleeding history or predisposition, 1 point: liable international normalized ratio, not assessed: ethanol or 
drug abuse, 1 point: drug predisposing to bleeding, 1 point. 
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary 





Table S4. Baseline characteristics of ablated and rate control only patients before and after propensity score weighting. 
 Ablation 
(N=9,185) 





Rate control only 
 (N=7,368) 
SMD 
Demographic       
Age, years  57 (50, 65) 68 (61, 75)    92.6% 60 (52, 68) 61 (52, 69) 2.7% 
Male 76.3% 65.0% 24.8% 73.3% 72.8% 1.3% 
High income status 54.9% 45.0% 19.9% 51.3% 50.5% 1.6% 
AF duration, months 24.4 (7.1, 56.7) 20.0 (2.4, 37.5]     23.8% 14.4 (4.2, 41.5) 11.4 (0.9, 37.5) 3.1% 
Risk scores       
CHA2DS2-VASc score 4.0 (2.0, 5.0)  2.0 (1.0, 3.0) 87.6% 2.0 (1.0, 4.0) 2.0 (1.0, 4.0) 1.7% 
mHAS-BLED score 3.0 (2.0, 4.0)  2.0 (2.0, 3.0) 48.6% 1.6 (1.0, 2.6) 2.1 (0.9, 3.2) 7.1% 
Charlson comorbidity index  4.0 (2.0, 7.0)  3.0 (2.0, 5.0) 49.9% 3.0 (2.0, 5.0) 3.0 (2.0, 5.0) 0.6% 
Hospital frailty risk score  2.0 (0.0, 7.4)  1.1 (0.0, 3.4) 66.5% 1.2 (0.0, 3.8) 0.7 (0.0, 3.6) 3.0% 
Comorbidities       
Heart failure 32.0% 49.8% 36.8% 33.4% 33.7% 0.8% 
Hypertension 77.0% 88.2% 29.7% 76.3% 75.4% 2.1% 
Diabetes 13.8% 28.1% 35.9% 18.0% 18.0% 0.2% 
Dyslipidemia 81.2% 75.3% 14.5% 77.4% 76.0% 3.2% 
Ischemic stroke 15.7% 36.8% 49.4% 20.5% 21.3% 2.2% 
TIA 7.8% 9.7% 6.5% 8.1% 7.9% 0.7% 
Hemorrhagic stroke 1.3% 3.8% 15.7% 1.7% 1.8% 0.4% 
Myocardial infarction 10.4% 16.4% 17.7% 10.9% 10.8% 0.2% 
Peripheral arterial disease 10.5% 16.4% 17.3% 11.4% 11.4% 0.2% 
Chronic kidney disease 4.0% 7.6% 15.3% 5.0% 4.7% 1.3% 
End stage renal disease 0.5% 1.4% 9.4% 0.8% 0.8% 0.8% 
Proteinuria 4.9% 6.0% 4.6% 5.3% 5.2% 0.4% 
Hyperthyroidism 18.6% 13.5% 13.7% 16.0% 15.7% 1.1% 
Hypothyroidism 15.5% 12.3% 9.4% 13.0% 12.5% 1.3% 
Malignancy 18.4% 21.9% 8.9% 17.9% 18.3% 1.0% 
COPD 19.6% 31.1% 26.8% 21.6% 22.1% 1.0% 
Liver disease 43.5% 38.8% 9.5% 40.8% 40.2% 1.1% 
Hypertrophic cardiomyopathy 1.9% 3.0% 7.6% 2.6% 2.5% 0.4% 
History of bleeding                     28.8% 31.1% 5.1% 28.1% 27.7% 0.8% 
Osteoporosis 15.5% 26.0% 26.2% 18.7% 18.7% 0.1% 
Sleep apnea 2.0% 0.5% 13.8% 1.3% 1.2% 1.2% 
Medication (Treatment)       
OAC 59.1% 73.2% 30.2% 50.4% 50.5% 0.3% 
Antiplatelet agents 73.4% 65.6% 17.1% 63.0% 61.3% 3.5% 
ACE-inhibitor/ARB                     47.4% 62.4% 30.6% 49.4% 48.5% 1.8% 
Diuretics 33.3% 58.7% 52.6% 39.7% 39.8% 0.1% 
K sparing diuretics 6.6% 17.8% 34.6% 9.1% 9.4% 0.9% 
Statin 38.6% 37.6% 2.0% 36.9% 36.0% 1.9% 
Values are presented as median (Q1, Q3, quartiles [25th and 75th percentiles]) or %. *Modified HAS-BLED=hypertension, 1 point: >65 years 
old, 1 point: stroke history, 1 point: bleeding history or predisposition, 1 point: liable international normalized ratio, not assessed: ethanol or 
drug abuse, 1 point: drug predisposing to bleeding, 1 point. 
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary 

























(95% CI) * 
p-value 
Ablation vs. Medical Therapy 
 Medical Therapy (N=6,621) Ablation (N=6,621)    
Primary outcome† 1,977 46,129 4.3 643 29,707 2.2 2.1 (1.9-2.4) 0.48 (0.44-0.53) <0.001 
All-cause death 869 50,472 1.7 255 31,560 0.8 0.9 (0.7-1.1) 0.44 (0.38-0.51) <0.001 
Heart failure 567 48,725 1.2 172 30,573 0.6 0.6 (0.4-0.7) 0.46 (0.39-0.55) <0.001 
Stroke/SE 1071 46,902 2.3 280 30,311 0.9 1.4 (1.1-1.6) 0.40 (0.35-0.45) <0.001 
Ablation vs. Antiarrhythmic drug 
 Antiarrhythmic drug (N=6,065) Ablation (N=6,065)    
Primary outcome† 1,695 41,581 4.1 601 27,034 2.2 1.9 (1.6-2.1) 0.52 (0.48-0.58) <0.001 
All-cause death 712 45,047 1.6 240 28,774 0.8 0.7 (0.6-0.9) 0.49 (0.42-0.57) <0.001 
Heart failure 496 43,629 1.1 164 27,824 0.6 0.6 (0.4-0.7) 0.50 (0.42-0.60) <0.001 
Stroke/SE 905 42,256 2.1 261 27,623 0.9 1.4 (1.2-1.6) 0.45 (0.39-0.51) <0.001 
Ablation vs. Rate control only 
 Rate control only (N=3,903) Ablation (N=3,903)    
Primary outcome† 1,574 27,878 5.6 445 17,164 2.6 3.1 (2.7-3.5) 0.43 (0.39-0.48) <0.001 
All-cause death 827 31,462 2.6 192 18,447 1.0 1.6 (1.3-1.8) 0.38 (0.32-0.44) <0.001 
Heart failure 465 29,889 1.6 126 17,745 0.7 0.8 (0.6-1.1) 0.43 (0.35-0.52) <0.001 
Stroke/SE 828 28,692 2.9 188 17,611 1.1 1.8 (1.5-2.1) 0.35 (0.30-0.41) <0.001 
*Adjusted for age, sex, income, AF duration, CHA2DS2-VASc score, modified HAS-BLED score, hospital frailty risk score, Charlson comorbidity index, 
hypertension, diabetes, ischemic stroke/TIA, myocardial infarction, peripheral arterial disease, hypertrophic cardiomyopathy, chronic kidney disease, end 
stage renal disease, liver disease, malignancy, hyperthyroidism, hypothyroidism, venous thromboembolism, COPD, intracranial bleeding, cardioversion, 
history of bleeding, baseline use of warfarin, NOAC, aspirin, clopidogrel, beta-blocker, ACE-inhibitor/ARB, dihydropyridine/nondihydropyridine calcium 
channel blocker, Class Ic and III antiarrhythmic drug, statin, diuretics, and digoxin, and OAC coverage rate of time at risk.† The primary clinical outcome 
was a composite endpoint of all-cause death, heart failure and ischemic stroke/SE. 
CI, confidence interval; PYs, person-years; SE, systemic embolism. Other abbreviations are same as table S3.  





















Ablation vs. Patients without AF 
 No AF (N= 439,128) Ablation (N= 9,422)    
Primary outcome 31,925 3,125,245 1.0 5,886 313,579 1.9 -0.8 (-0.9 ~ -0.8) 1.66 (0.91-3.04) 0.099 
All-cause death 19,070 3,172,406 0.6 2,306 329,211 0.7 -0.1 (-0.1 ~ -0.0) 1.77 (0.81-3.90) 0.154 
Heart failure 2,730 3,164,886 0.1 814 321,969 0.3 -0.2 (-0.2 ~ -0.1) 2.10 (0.84-5.26) 0.115 
Stroke/SE 11,696 3,137,176 0.4 2,684 317,214 0.8 -0.5 (-0.5 ~ -0.4) 2.18 (0.72-6.28) 0.071 
* Adjusted for age, sex, income, AF duration, CHA2DS2-VASc score, modified HAS-BLED score, hospital frailty risk score, Charlson 
comorbidity index, hypertension, diabetes, ischemic stroke/TIA, myocardial infarction, peripheral arterial disease, hypertrophic cardiomyopathy, 
chronic kidney disease, end stage renal disease, liver disease, malignancy, hyperthyroidism, hypothyroidism, venous thromboembolism, COPD, 
intracranial bleeding, cardioversion, history of bleeding, baseline use of warfarin, NOAC, aspirin, clopidogrel, beta-blocker, ACE-
inhibitor/ARB, dihydropyridine/nondihydropyridine calcium channel blocker, Class Ic and III antiarrhythmic drug, statin, diuretics, and digoxin, 
and OAC coverage rate of time at risk. 





Table S7. Risk of falsification endpoints in propensity score weighted or 1:1 propensity score matched ablated and different control 
patients. 
 Propensity score weighted 1:1 propensity score matched 
 HR (95% CI) p-value HR (95% CI) p-value 
Urinary tract infection     
  Ablation vs. Medical Therapy 0.99 (0.94-1.04) 0.583 0.99 (0.93-1.06) 0.819 
Ablation vs. Antiarrhythmic drug 0.98 (0.93-1.03) 0.416 0.98 (0.92-1.05) 0.536 
  Ablation vs. Rate control only 0.95 (0.90-1.01) 0.096 0.94 (0.87-1.02) 0.141 
Varicella-zoster virus infection     
  Ablation vs. Medical Therapy 1.09 (1.01-1.18) 0.033 1.11 (1.01-1.22) 0.030 
Ablation vs. Antiarrhythmic drug 1.06 (0.98-1.15) 0.157 1.02 (0.93-1.13) 0.625 
  Ablation vs. Rate control only 1.12 (1.02-1.22) 0.014 1.15 (1.02-1.29) 0.025 
Fall accident      
  Ablation vs. Medical Therapy 1.07 (0.59-1.93) 0.834 1.46 (0.63-3.39) 0.381 
Ablation vs. Antiarrhythmic drug 1.25 (0.67-2.33) 0.486 1.76 (0.69-4.51) 0.237 
  Ablation vs. Rate control only 0.91 (0.48-1.74) 0.775 1.79 (0.78-4.13) 0.172 
HR, hazard ratio; CI, confidence interval. 
 
